Hematology

Latest News

Video Series

Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

The Future of CAR T-Cell Therapy in LBCL

The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

Bridging Therapy With CAR T-Cell Therapy in LBCL

Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

CAR T-Cell Therapy as a Second-Line Treatment for LBCL

Sequencing With CAR T-Cell Therapy for LBCL

The Expanding Utility of CAR T-Cell Therapy in LBCL

Latest Videos

Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.

Prerna Mewawalla, MD, on Unmet Needs Following Early-Line CAR T for R/R Multiple Myeloma

Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford

Surbhi Sidana, MD, on Cilta-Cel's Efficacy in Second-Line Relapsed/Refractory Multiple Myeloma

Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California

Alexey Danilov, MD, PhD, on CAR T and Bispecific Antibody Sequencing for DLBCL

Tami John, MD, on β-Thalassemia Gene Therapy in the Context of the Broader World

Tami John, MD, on Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD, on Barriers to Access for Gene Therapy in β-Thalassemia

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Matthew Ku, MBBS, PhD, FRACP, RACP, FRCPA/RCPA, on CAR T-Cell Therapy JNJ-90014496's Safety Profile in R/R LBCL

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Saurabh Dahiya, MD, FACP, on CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Shahzad Raza, MD, on Future Plans for CAR T-Cell Therapy NXC-201 in R/R Light Chain Amyloidosis

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Manali Kamdar, MD, on Lowering Barriers to Access for Liso-Cel Based on New Data

Shorts

0:47

The Importance of Nonmyeloablative Chemotherapy to Cell Therapy

2 months ago

Michael T. Lotze, MD

Podcasts

September 15, 2025

ImmunoLogic, Episode 6: "Tailor-Made Immunity: The Promise of Personalized Neoantigen Vaccines” With Stephen Schoenberger, PhD

July 30, 2025

ImmunoLogic, Episode 5: "Tumor Infiltrators and Triumphs: The Evolution of TIL Therapy" With Michael T. Lotze, MD

May 29, 2025

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

April 8, 2025

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

March 11, 2025

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

January 31, 2025

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

December 18, 2024

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

CME Content

In-Person + Virtual Event

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

October 26, 2025

Video

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Video

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Video

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Eytan M. Stein, MD; Marina Kremyanskaya, MD, PhD; Hannah Levavi, MD

Video

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Rami Komrokji, MD; Maen Hussein, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

Video

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Craig Emmitt Cole, MD; Sikander Ailawadhi, MD; Irene Ghobrial, MD; Monique Hartley-Brown, MD, MMSc

Multimedia

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Elias Jabbour, MD

Video

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Cristina Gasparetto, MD; Katja Weisel, MD

Video

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Rami S. Komrokji, MD; Ghaith Abu-Zeinah, MD; Gabriela Hobbs, MD; Barbara Mora, MD

Video

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Krina Patel, MD, MSc; Alfred L. Garfall, MD; Ajay K. Nooka, MD, MPH, FACP

Video

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Corey Cutler, MD, MPH, FRCPC; Amin M. Alousi, MD; Yi-Bin Chen, MD; Carrie Lynn Kitko, MD

Video

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Alexey V. Danilov, MD, PhD; Leidy L. Isenalumhe, MD, MS; Lori A. Leslie, MD; Mazyar Shadman, MD, MPH; Jason R. Westin, MD, MS, FACP

Video

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

Video

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Catherine C. Coombs, MD, MS; Paolo Ghia, MD, PhD; Tycel J. Phillips, MD; Jeffrey V. Matous, MD; Grzegorz S. Nowakowski, MD, FASCO

Case-based Simulation

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

Amrita Krishnan, MD

In-Person Event

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 26-28, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

In-Person + Virtual Event

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

April 25-26, 2026

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Video

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

André H. Goy, MD; Jorge E. Cortes, MD; Sagar Lonial, MD, FACP

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

In-Person Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11, 2026

Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

Orca Bio’s BLA for Hematologic Malignancy Cell Therapy Orca-T Accepted by FDA With Priority Review

ByNoah Stansfield

October 7th 2025

The PDUFA target action date for the BLA has been set at April 6, 2026.

Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102

ByNoah Stansfield

October 6th 2025

The company cited strategic prioritization as the reason for its decision.

CGTLive®’s Weekly Rewind – October 3, 2025

ByNoah Stansfield

October 3rd 2025

Review top news and interview highlights from the week ending October 3, 2025.

Umoja Biopharma's In Situ CAR T Therapy UB-VV111 Fast-Tracked for Several R/R B-Cell Malignancy Indications

ByNoah Stansfield

October 2nd 2025

UB-VV111 is currently being evaluated in a phase 1 clinical trial for adult patients with R/R CD19+ B-cell malignancies.

Around the Helix: Cell and Gene Therapy Company Updates – October 1, 2025

ByNoah Stansfield

October 1st 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

News in Cell and Gene Therapy for Rare Cancer Day 2025

ByNoah Stansfield

September 30th 2025

In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news related to cell therapy for such indications.

CGTLive®’s Weekly Rewind – September 26, 2025

ByNoah Stansfield

September 26th 2025

Review top news and interview highlights from the week ending September 26, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – September 24, 2025

ByNoah Stansfield

September 24th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – September 19, 2025

ByNoah Stansfield

September 19th 2025

Review top news and interview highlights from the week ending September 19, 2025.

Heather Landau, MD, the MSKCC Amyloidosis Program director and the NEXICART-2 principal study investigator

Phase 1/2 Trial for Immix Biopharma’s AL Amyloidosis CAR T NXC-201 Hits Over 50% Enrollment

ByNoah Stansfield

September 18th 2025

The trial, which is taking place in the United States, is expected to enroll 40 patients in total.

Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

ByNoah Stansfield

September 17th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025

ByNoah Stansfield

September 15th 2025

For World Lymphoma Awareness Day, held annually on September 15, take a look at the stories that have stood out in lymphoma cell therapy in recent months.

CGTLive®’s Weekly Rewind – September 12, 2025

ByNoah Stansfield

September 12th 2025

Review top news and interview highlights from the week ending September 12, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025

ByNoah Stansfield

September 10th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – September 5, 2025

ByNoah Stansfield

September 5th 2025

Review top news and interview highlights from the week ending September 5, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – September 3, 2025

ByNoah Stansfield

September 3rd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

FDA Activity Recap: August 2025 Features Papillomatosis Gene Therapy Approval, Eli-Cel Labelling Update, and More

ByNoah Stansfield

September 1st 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

CGTLive®’s Weekly Rewind – August 29, 2025

ByNoah Stansfield

August 29th 2025

Review top news and interview highlights from the week ending August 29, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – August 27, 2025

ByNoah Stansfield

August 27th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Prerna Mewawalla, MD, the medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network

Unmet Needs Following Early-Line CAR-T for R/R Multiple Myeloma

ByPrerna Mewawalla, MD,Noah Stansfield

August 27th 2025

Prerna Mewawalla, MD, the medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, spoke on unmet needs in patients who receive early-line CAR-T for R/R MM.

Surbhi Sidana, MD, an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University

Cilta-Cel's Efficacy in Second-Line Relapsed/Refractory Multiple Myeloma

BySurbhi Sidana, MD,Noah Stansfield

August 24th 2025

Surbhi Sidana, MD, the assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford discussed the benefit of second-line cilta-cel in PFS and OS.